Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The aims of this clinical review are to: (i) highlight the importance of elevated baseline triglycerides (TG) in the setting of well-controlled low-density lipoprotein cholesterol (LDL-C) on statins as a major contributor to residual atherosclerotic cardiovascular disease (ASCVD) risk, particularly among patients with type 2 diabetes mellitus, metabolic syndrome, and obesity whose distinctive lipid phenotype cannot be optimally treated with LDL-C reduction therapy alone; (ii) describe the findings and clinical implications of the landmark REDUCE-IT trial in which ethyl eicosapentaenoic acid significantly improved ASCVD outcomes. While many genetic studies have shown that elevated TG are an independent causal factor for ASCVD, prior placebo-controlled trials using niacin, fibrates, omega-3 fatty acids, and dietary supplement fish oil preparations have failed to demonstrate significant CV event reduction when added to statin therapy. In contrast, the REDUCE-IT trial in 8179 participants showed convincingly that the administration of 4 g daily of icosapent ethyl (an ethyl ester of eicosapentaenoic acid) in patients at high risk for ASCVD with increased levels of baseline TG [median value, 2.44 mmol/L (216.0 mg/dL)] but well-controlled LDL-C [median value, 1.94 mmol/L (75.0 mg/dL)] reduced significantly incident events across both the trial primary endpoint and multiple prespecified secondary endpoints, including cardiovascular death, as well as both subsequent and total primary endpoint and key secondary endpoint events. Icosapent ethyl unequivocally contributed to ASCVD event reduction over and above statin therapy. The REDUCE-IT trial results should alter our approach to managing a growing population of hypertriglyceridaemic patients whose lipid phenotype requires more intensive treatment beyond LDL-C lowering alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Besides LDL-C, hypertriglyceridaemia is thought to contribute to development and progression of atherosclerotic coronary plaques”
From Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis (2024) · cites this paper as [9]
In the citing paper
“also debated are specific benefits of eicosapentaenoic acid (EPA)”
From Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis (2024) · cites this paper as [9]
In the citing paper
“Benefits of pharmacologic omega-3 fatty acid administration in cardiovascular prevention are controversial.”
From Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis (2024) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationRubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Self-citationEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“Multiple prior placebocontrolled trials in the statin era, which tested the co-administration of fibrates or niacin, have failed to demonstrate incremental ASCVD event reduction after ‘optimally controlled’ LDL-C levels have been achieved with statins.(24) Notably, therapies such as fibrates (in particular gemfibrozil…”
BackgroundInterpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Research works printed but not linked: 15
- Hong, 2017, How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD, J Am Coll Cardiol, 70, 2171, 10.1016/j.jacc.2017.09.001 · DOI · Paper page
- Rosinger, 2017, Trends in total cholesterol, triglycerides, and low-density lipoprotein in US adults, 1999-2014, JAMA Cardiol, 2, 339, 10.1001/jamacardio.2016.4396 · DOI · Paper page
- Amber, 2013, Dyslipidaemia and atherosclerotic vascular disease: DYSIS results in the UK, Br J Cardiol, 20, S9
- Musunuru, 2016, Surprises from genetic analyses of lipid risk factors for atherosclerosis, Circ Res, 118, 579, 10.1161/CIRCRESAHA.115.306398 · DOI · Paper page
- Chapman, 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, Eur Heart J, 32, 1345, 10.1093/eurheartj/ehr112 · DOI · Paper page
- Robinson, 2012, Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials, Am J Cardiol, 110, 1468, 10.1016/j.amjcard.2012.07.007 · DOI
- Kohli, 2009, Resolvins and protectins: mediating solutions to inflammation, Br J Pharmacol, 158, 960, 10.1111/j.1476-5381.2009.00290.x · DOI · Paper page
- Alexander, 2017, A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk, Mayo Clin Proc, 92, 15, 10.1016/j.mayocp.2016.10.018 · DOI · Paper page
- Rizos, 2012, Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis, JAMA, 308, 1024, 10.1001/2012.jama.11374 · DOI · Paper page
- Bucher, 2002, N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials, Am J Med, 112, 298, 10.1016/S0002-9343(01)01114-7 · DOI · Paper page
- Kwak, 2012, Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials, Arch Intern Med, 172, 686, 10.1001/archinternmed.2012.262 · DOI
- Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 · DOI · Paper page
- Nosaka, 2017, Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study, Int J Cardiol, 228, 173, 10.1016/j.ijcard.2016.11.105 · DOI · Paper page
- Aung, 2018, Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals, JAMA Cardiol, 3, 225, 10.1001/jamacardio.2017.5205 · DOI · Paper page
- Orringer, 2019, National Lipid Association position on the use of icosapent ethyl in high and very high risk patients, Clin Lipid Update, 2019
Cited by
Budoff, M. J., Bhatt, D. L., Kinninger, A., Lakshmanan, S., Muhlestein, J. B., Le, V. T., May, H. T., Shaikh, K., Shekar, C., Roy, S. K., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa652 · Cited by 446
Self-citationEmerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407
Self-citationCauses and consequences of hypertriglyceridemia
Packard, C. J., Boren, J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00252 · Cited by 239
“Finally, it is recognized increasingly that the size of the unmet clinical need is substantial in the “real-world” where surveys have revealed a high prevalence of persistent hypertriglyceridemia in well-treated patients with established ASCVD (126), and in patients with diabetes and metabolic syndrome (127, 128).”
BackgroundThe role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus
Hu, X., Liu, Q., Guo, X., Wang, W., Yu, B., Liang, B., Zhou, Y., Dong, H., & Lin, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01554-0 · Cited by 150
Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies
Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa117 · Cited by 103
Self-citation
Metadata
- Authors
- Boden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F.
- Affiliations
- VA New England Healthcare System, Boston University School of Medicine , 150 S. Huntington Avenue, Boston, MA 02130, USA
- Brigham and Women’s Hospital Heart & Vascular Center , Harvard Medical School, Boston, MA, USA
- CGH Medical Center , Sterling, IL, USA
- Imperial Centre for Cardiovascular Disease Prevention, School of Public Health , Imperial College London, London, UK
- Sorbonne University, Pitie-Salpetriere University Hospital , Paris, France
- University Heart Center, University Hospital , Zurich, Switzerland
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-23
- Volume
- 41
- Issue
- 24
- Pages
- 2304-2312
- ISSN
- 0195-668X
- 1522-9645
- PMC
- PMC7308541
- Cited by
- 72
- References
- 41
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. https://app.cochat.ai/papers/10.1093/eurheartj/ehz778
- The paper
- Boden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F. (2020). Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz778
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.